Report from Annual General Meeting of Vitrolife AB (publ)

Rhea-AI Summary

Vitrolife held its Annual General Meeting, approving several key decisions for 2025. Shareholders approved a dividend of SEK 1.10 per share for 2024, with May 2, 2025, set as the record date.

The board saw the re-election of five members, with Jón Sigurdsson appointed as Chairman. Total board remuneration increased to SEK 3.67 million, up from SEK 3.3 million. Deloitte AB was re-elected as auditor.

Key authorizations granted include:

• Permission to issue up to 13,544,719 shares (10% of share capital)
• Authority to acquire company shares (max 10% of total shares)
• Implementation of a share-based incentive program with 480,000 warrants

The meeting also approved new guidelines for executive management compensation.

Positive

• Dividend payment of SEK 1.10 per share approved for 2024
• Board authorization to issue up to 13.5M new shares (10% of capital) for potential growth opportunities
• Implementation of share-based incentive program to align management interests with shareholders

Negative

• Board remuneration increased by 11.2% to SEK 3.67M from SEK 3.3M
• Potential share dilution risk up to 10% from new share issuance authorization
• Additional dilution possible from 480,000 warrants issued for incentive program

GOTHENBURG, Sweden, April 30, 2025 /PRNewswire/ -- At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

• Resolution in accordance with the Board's proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
• Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.
• Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which SEK 1 350 000 (1 200 000) to the Chairman of the Board, SEK 450 000 (400 000) to each of the other members of the Board, SEK 160 000 (150 000) to the Chairman of the Audit Committee and SEK 80 000 (75 000) to each of the other members of the Audit Committee.
• Re-election of Deloitte AB as auditor with unchanged remuneration principles.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
• The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
• Implementation of a share-based incentive program including issue of a maximum number of 480,000 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities.

Gothenburg, April 29, 2025
VITROLIFE AB (publ)
The Board

The information was submitted for publication, through the agency of the contact persons set out above, at 30-04-2025 09:08 CET.

Contact: 

Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/report-from-annual-general-meeting-of-vitrolife-ab--publ-,c4143317

The following files are available for download:

https://mb.cision.com/Main/1031/4143317/3421054.pdf

Report from Annual General Meeting of Vitrolife AB (publ)

 

View original content:https://www.prnewswire.com/news-releases/report-from-annual-general-meeting-of-vitrolife-ab-publ-302442384.html

SOURCE Vitrolife AB (publ)

FAQ

What dividend did Vitrolife (VTRLY) announce for 2024?

Vitrolife announced a dividend of SEK 1.10 per share for the financial year 2024, with May 2, 2025 set as the record date.

How many shares can Vitrolife (VTRLY) issue under the new authorization in 2025?

The Board was authorized to issue up to 13,544,719 shares, which represents just below 10% of Vitrolife's share capital.

What is the new Board compensation structure for Vitrolife (VTRLY) in 2025?

Total Board remuneration was set at SEK 3,670,000, with the Chairman receiving SEK 1,350,000, regular Board members SEK 450,000 each, Audit Committee Chair SEK 160,000, and Committee members SEK 80,000 each.

How many warrants did Vitrolife (VTRLY) approve in their 2025 incentive program?

Vitrolife approved the issuance of up to 480,000 warrants as part of a share-based incentive program to be managed by a wholly owned subsidiary.

What share buyback authorization was approved at Vitrolife's 2025 AGM?

The Board was authorized to acquire company shares on multiple occasions until the next AGM, with a limit of holding no more than 10% of total shares at any time.